CTLA4 and melanoma: The H11-VHHkappa conjugate showed superior efficacy in the MC38 model compared to the anti-CTLA-4 mAb 9H10 (Fig. 3A) and showed similar efficacy in the B16-F10 melanoma model (Fig. 3B).